Bausch, Lannett settlements with US states get final nod in generic drug antitrust case
( May 27, 2026, 16:48 GMT | Official Statement) -- MLex Summary: Bausch Health and Lannett Company’s settlements with US states have been granted final approval to resolve allegations that they conspired to artificially inflate and manipulate prices for numerous generic prescription drugs. Bausch agreed to pay $4.1 million, and Lannett agreed to pay $13.8 million.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.